CN110507661A - A kind for the treatment of of allopecia composition - Google Patents

A kind for the treatment of of allopecia composition Download PDF

Info

Publication number
CN110507661A
CN110507661A CN201910516744.1A CN201910516744A CN110507661A CN 110507661 A CN110507661 A CN 110507661A CN 201910516744 A CN201910516744 A CN 201910516744A CN 110507661 A CN110507661 A CN 110507661A
Authority
CN
China
Prior art keywords
treatment
allopecia
externally applied
applied drug
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910516744.1A
Other languages
Chinese (zh)
Inventor
唐安平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201910516744.1A priority Critical patent/CN110507661A/en
Publication of CN110507661A publication Critical patent/CN110507661A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Abstract

The present invention provides a kind for the treatment of of allopecia compositions, it is made of medicine for oral administration and externally applied drug or is individually made of externally applied drug, the medicine for oral administration includes the Finasteride and suitable starch of 0.5-2mg, and the externally applied drug includes the menthol of the minoxidil of 1.0-5.0%, 1%, and surplus is solvent.Implementing technical solution of the present invention, to alopecia, especially heredity alopecia seborrheica, there is significant therapeutic effect by being used cooperatively Finasteride and minoxidil preparation.

Description

A kind for the treatment of of allopecia composition
Technical field
The present invention relates to hair restorer technical field, in particular to a kind for the treatment of of allopecia composition.
Background technique
The hair normally to fall off is at the hair of catagen and stand-down, grows due to entering catagen and newly entering The hair of phase is constantly in dynamic equilibrium, therefore can maintain the hair of normal quantity.Pathologic alopecia refers to that hair is abnormal or excessive Fall off, there are many reason, mainly include androgenetic alopecia, nervous baldness, endocrine alopecia, trophism alopecia, physics Property alopecia, alopecia of chemical origin, infectious alopecia, symptomatic alopecia, congenital alopecia, seasonal alopecia, wherein further including heredity Property alopecia seborrheica, heredity alopecia seborrheica be it is simultaneous with Seborrhea, seborrhea, mostly with hereditary base Cause, male sex hormone are related with mental element.
Currently, one of which is minoxidil, from the 1990s there are mainly two types of the products prevented hair loss on the market It rises, minoxidil is just used with 2% concentration (no prescription) and 3% and 5% concentration (by prescription) with localized forms.Although Research has shown that the validity of 5% minoxidil is better than the minoxidil of 2% concentration, but minoxidil is promoting hair regeneration side The validity in face is lower than 40%.Minoxidil is considered as the local gold standard that can be used for hair growth.Another right and wrong That male amine, is usually administered orally with 1mg/ days dosage, inhibits the effect of alopecia to reach 90% or so, natural on-off cycles of hair growth increases Effect reach 65% or so, significant effect, but the health giving quality of controlling of Finasteride remains unchanged for heredity alopecia seborrheica It is lower.
Summary of the invention
In order to solve the above-mentioned technical problem, a kind for the treatment of of allopecia composition, technical side of the invention are disclosed in the present invention Case is implemented:
A kind for the treatment of of allopecia composition, is made of medicine for oral administration and externally applied drug or is individually made of externally applied drug, described for oral administration Medicine includes the Finasteride and suitable starch of 0.5-2mg, the externally applied drug include the minoxidil of 1.0-5.0%, 1% it is thin Lotus brain, surplus are solvent.The composition is used to reduce alopecia in people's object and/or increases hair regeneration.
Preferably, the Finasteride that the medicine for oral administration is 0.5-2mg and tablet or pill that suitable starch is mixed Or capsule, the preparation that the externally applied drug is the minoxidil of 1.0-5.0%, 1% menthol and suitable solvent are mixed.
Preferably, the solvent is selected from one or both of alcohol, dimethanol, and the volume fraction of the alcohol is 75%.
Preferably, a kind for the treatment of of allopecia composition above-mentioned, is made of medicine for oral administration and externally applied drug, and the medicine for oral administration includes The Finasteride of 1mg and suitable starch, the externally applied drug include 2.5% minoxidil, 1% menthol, and surplus is molten Agent.The composition people's object is male.
Preferably, a kind for the treatment of of allopecia composition above-mentioned, is made of externally applied drug, and the externally applied drug includes 2.5% rice Promise ground you, 1% menthol, surplus is solvent.The composition people's object is women.
Implement technical solution of the present invention, to alopecia, especially to lose by being used cooperatively Finasteride and minoxidil Transmissibility alopecia seborrheica has significant therapeutic effect, relative to be used alone Finasteride or minoxidil preparation its about The health giving quality of controlling of heredity alopecia seborrheica significantly improves.In addition, the application be added in minoxidil preparation menthol at Point, people can not only be allowed to feel that brain is refrigerant, have the effect of refreshing, sebum secretion can also be inhibited, cooperated with minoxidil, Alopecia seborrheica can effectively be treated.
Specific embodiment
The technical scheme in the embodiments of the invention will be clearly and completely described below, it is clear that described implementation Example is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field is common Technical staff's every other embodiment obtained without creative efforts belongs to the model that the present invention protects It encloses.
Embodiment 1: patient Tang so-and-so, male, heredity alopecia seborrheica, natural alopecia is fast to form Mediterranean shape, 40 years old When start to be treated with Finasteride, receiving be Mo Shadong guarantor's method only treat two courses for the treatment of, one the course for the treatment of three months, altogether treat Six months, alopecia continued, and without effect, abandoned treating.Start to begin to use a kind for the treatment of of allopecia group of the present invention within 48 years old Object is closed, application method: every night takes the medicine for oral administration containing 1mg Finasteride orally, is combed three times with liquid feeding in alopecia portion in the morning, afternoon and evening Position puts the externally applied drug containing 2.5% minoxidil on the skin, and after two courses for the treatment of (course for the treatment of 6 months), alopecia stops, and number of hairs is bright It is aobvious to increase.
Embodiment 2: patient Yin so-and-so, male, heredity alopecia seborrheica starts to begin to use of the present invention one for 46 years old Kind treatment of allopecia composition, application method: every night takes the medicine for oral administration containing 1mg Finasteride orally, uses add three times in the morning, afternoon and evening Liquid comb puts the externally applied drug containing 2.5% minoxidil on the skin at alopecia position, and after four courses for the treatment of (course for the treatment of 6 months), alopecia stops Only, and number of hairs is kept.
Embodiment 3: patient thanks so-and-so, and male, heredity alopecia seborrheica starts to begin to use of the present invention one for 46 years old Kind treatment of allopecia composition, application method: every night takes the medicine for oral administration containing 1mg Finasteride orally, uses add three times in the morning, afternoon and evening Liquid comb puts the externally applied drug containing 2.5% minoxidil on the skin at alopecia position, and after course for the treatment of (course for the treatment of 6 months), alopecia stops Only, after two courses for the treatment of, number of hairs increases.
Embodiment 4: patient Mr. Li, male, heredity alopecia seborrheica have formed Mediterranean shape, and forehead hair is few, and 25 Year starts to begin to use a kind for the treatment of of allopecia composition of the present invention, application method: every night it is for oral administration containing 1mg it is non-that The medicine for oral administration of male amine is combed three times with liquid feeding put the externally applied drug containing 2.5% minoxidil, a course for the treatment of on the skin at alopecia position in the morning, afternoon and evening After (course for the treatment of 6 months), alopecia stops, and hair amount starts to increase after two courses for the treatment of.
It should be pointed out that the foregoing is merely illustrative of the preferred embodiments of the present invention, it is not intended to limit the invention, it is all Within the spirit and principles in the present invention, any modification, equivalent replacement, improvement and so on should be included in guarantor of the invention Within the scope of shield.

Claims (8)

1. a kind for the treatment of of allopecia composition, which is characterized in that it is made of medicine for oral administration and externally applied drug or is individually made of externally applied drug, The medicine for oral administration includes the Finasteride and suitable starch of 0.5-2mg, and the externally applied drug includes the minot of 1.0-5.0% You, 1% menthol, surplus is solvent.
2. a kind for the treatment of of allopecia composition according to claim 1, which is characterized in that the medicine for oral administration is 0.5-2mg's Tablet or pill or capsule that Finasteride and suitable starch are mixed, the externally applied drug are the minot of 1.0-5.0% The preparation that you, 1% menthol and suitable solvent are mixed.
3. a kind for the treatment of of allopecia composition according to claim 1, which is characterized in that the solvent is selected from alcohol, diformazan One or both of alcohol, the volume fraction of the alcohol are 75%.
4. a kind for the treatment of of allopecia composition according to claim 1, which is characterized in that it is made of medicine for oral administration and externally applied drug, The medicine for oral administration includes the Finasteride and suitable starch of 1mg, the externally applied drug include 2.5% minoxidil, 1% it is thin Lotus brain, surplus are solvent.
5. a kind for the treatment of of allopecia composition according to claim 1, which is characterized in that be made of externally applied drug, the external application Medicine includes 2.5% minoxidil, 1% menthol, and surplus is solvent.
6. a kind of according to claim 1, treatment of allopecia composition described in any one of 4,5, is used in people's object reduce Alopecia and/or increase hair regeneration.
7. a kind for the treatment of of allopecia composition according to claims 4, which is characterized in that people's object is male.
8. a kind for the treatment of of allopecia composition according to claims 5, which is characterized in that people's object is women.
CN201910516744.1A 2019-06-14 2019-06-14 A kind for the treatment of of allopecia composition Pending CN110507661A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910516744.1A CN110507661A (en) 2019-06-14 2019-06-14 A kind for the treatment of of allopecia composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910516744.1A CN110507661A (en) 2019-06-14 2019-06-14 A kind for the treatment of of allopecia composition

Publications (1)

Publication Number Publication Date
CN110507661A true CN110507661A (en) 2019-11-29

Family

ID=68623155

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910516744.1A Pending CN110507661A (en) 2019-06-14 2019-06-14 A kind for the treatment of of allopecia composition

Country Status (1)

Country Link
CN (1) CN110507661A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1450890A (en) * 2000-08-09 2003-10-22 法马西雅公司 Novel compositions of minoxidil
CN104161739A (en) * 2014-08-15 2014-11-26 武汉人福药业有限责任公司 Finasteride capsule and preparation method thereof
CN104784139A (en) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 Preparation method of finasteride coating tablet
US20160213590A1 (en) * 2014-05-23 2016-07-28 Triple Hair, Inc. Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth
CN105902553A (en) * 2016-05-29 2016-08-31 山东仁和堂药业有限公司 Compound finasteride tablets and preparation process thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1450890A (en) * 2000-08-09 2003-10-22 法马西雅公司 Novel compositions of minoxidil
CN104784139A (en) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 Preparation method of finasteride coating tablet
US20160213590A1 (en) * 2014-05-23 2016-07-28 Triple Hair, Inc. Compositions for Reducing Hair Loss and/or Increasing Hair Regrowth
CN104161739A (en) * 2014-08-15 2014-11-26 武汉人福药业有限责任公司 Finasteride capsule and preparation method thereof
CN105902553A (en) * 2016-05-29 2016-08-31 山东仁和堂药业有限公司 Compound finasteride tablets and preparation process thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
中国中西医结合学会皮肤性病专业委员会: "《中国中西医结合皮肤性病学术会议论文汇编》", 30 November 2004 *
侯连兵等: "《现代个体化药物新剂型.西药卷》", 30 September 2009, 人民军医出版社 *
李世文等: "《老药新用途》", 31 January 2017, 河南科学技术出版社 *
李继俊: "《妇产科内分泌治疗学》", 31 May 2014, 人民军医出版社 *
杜鑫等: "口服非那雄胺联合米诺地尔搽剂治疗男性雄激素性脱发疗效观察", 《中日友好医院学报》 *
陈勇燕: "米诺地尔与非那雄胺对脱发的疗效观察", 《现代诊断与治疗》 *
陈树新等: "米诺地尔洗剂与非那雄胺合用治疗雄激素性脱发的临床疗效观察", 《国际医药卫生导报》 *

Similar Documents

Publication Publication Date Title
US8715714B2 (en) Uses of rare earth elements for hair improvement
US8883131B2 (en) Composition for the treatment of hair loss and baldness
CN108938485B (en) Hair growth liquid for preventing alopecia and preparation method thereof
US5108749A (en) Scalp treatment composition
JP2010501551A (en) Use of rare earth elements for hair improvement
WO2017010597A1 (en) Hair care cosmetic composition containing growth factor for promoting regeneration and growth of follicular cells, high-stability fibroblast growth factor variant, and noggin peptide
CN111228172A (en) High-efficiency hair loss prevention and hair growth composition
KR102535575B1 (en) A cosmetic composition for hair care comprising high stable Fibroblast Growth Factor-9 mutant
CN113197911A (en) Application of ginsenoside composition in preparing medicine for preventing and treating alopecia by acting on hair follicle tissues
KR100484236B1 (en) Hair Growth Promoting Composition
KR100664400B1 (en) Composition for preventing the hair from falling out
CN106937957B (en) Composition for treating androgenetic alopecia and shampoo thereof
CN110507661A (en) A kind for the treatment of of allopecia composition
KR101659316B1 (en) Composition for stimulating hair growth and preparation method thereof
CN102441006B (en) A kind of hair-regrowth solution containing chlorine dioxide and preparation and application thereof
KR102612128B1 (en) A cosmetic composition for hair containing an extract of Spiraea prunifolia
US20080267899A1 (en) Plant extract composition for hair growth
KR20200069711A (en) Scalp essences for scalp care
KR20090022224A (en) Cosmetic composition for scalp protection and trichogenousness
CN106309228A (en) Toothpaste for night use and preparation method thereof
KR20090059230A (en) Cosmetic composition for anti-alopecia and trichogenousness
KR20100111640A (en) Manufacturing method of cosmetic composition for trichogenousness or anti-alopecia
US20230042135A1 (en) Herbal shampoo composition and method for preparing the same
WO2021157753A1 (en) Composition for preventing hair loss and promoting hair regrowth
CN117017891A (en) Hair growth liquid capable of preventing seborrheic alopecia and preparation method of hair growth liquid

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191129